What is the price target for DERM stock?
10 analysts have analysed DERM and the average price target is 13.77 USD. This implies a price increase of 167.38% is expected in the next year compared to the current price of 5.15.
JOURNEY MEDICAL CORP (DERM) Forecast, Price Target & Analyst Ratings
NASDAQ:DERM • US48115J1097
Current stock price
5.15 USD
+0.02 (+0.39%)
At close:
5.15 USD
0 (0%)
After Hours:
Analyst forecast overview
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for JOURNEY MEDICAL CORP (DERM).
Forecast Snapshot
Next Earnings Forecast
Earnings Estimate- Release Date
- May 19, 2026
- Period
- Q1 / 2026
- EPS Estimate
- -$0.08
- Revenue Estimate
- 16.267M
Price Target Details & History
Consensus Price Target and Range
Mean target
$13.77
Upside
+ 167.38%
From current price of $5.15 to mean target of $13.77, Based on 10 analyst forecasts
Low
$12.12
Median
$13.26
High
$16.80
Price Target Revisions
1 Month
0.00%
3 Months
0.00%
Price Target Summary
10 Wall Street analysts provided a forecast for the next 12 months for DERM. The average price target is 13.77 USD. This implies a price increase of 167.38% is expected in the next year compared to the current price of 5.15.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
82.00%
DERM was analyzed by 10 analysts. The buy percentage consensus is at 82. So analysts seem to be very confident about DERM.
In the previous month the buy percentage consensus was at a similar level.
DERM was analyzed by 10 analysts. More opinions would make the average more meaningful.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-03-26 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-08-25 | HC Wainwright & Co. | Initiate | Buy |
| 2025-08-13 | Lake Street | Maintains | Buy -> Buy |
| 2025-07-30 | B. Riley Securities | Maintains | Buy -> Buy |
| 2024-09-06 | Lake Street | Initiate | Buy |
| 2024-08-22 | Rodman & Renshaw | Initiate | Buy |
| 2024-06-28 | Roth MKM | Reiterate | Buy |
| 2024-02-16 | Alliance Global Partners | Initiate | Buy |
| 2023-09-07 | B. Riley Securities | Reiterate | Buy -> Buy |
| 2023-07-12 | B. Riley Securities | Maintains | Buy -> Buy |
| 2023-05-23 | B. Riley Securities | Maintains | Buy -> Buy |
| 2023-03-30 | B. Riley Securities | Reiterate | Buy |
| 2022-02-25 | Cantor Fitzgerald | Initiate | Overweight |
| 2021-12-16 | Roth Capital | Initiate | Buy |
| 2021-12-07 | B. Riley Securities | Initiate | Buy |
Next Earnings Forecast Details
Next Earnings Details
- Release Date
- May 19, 2026
- Period
- Q1 / 2026
- EPS Estimate
- -$0.08
- Revenue Estimate
- 16.267M
- Revenue Q2Q
- 23.81%
- EPS Q2Q
- 56.08%
- Number of Analysts
- 6
Next Earnings Revisions
Revenue (1 Month)
-21.90%
Revenue (3 Months)
-21.90%
EPS (1 Month)
-158.33%
EPS (3 Months)
-158.33%
Next Earnings Summary
DERM is expected to report earnings on 5/19/2026. The consensus EPS estimate for the next earnings is -0.08 USD and the consensus revenue estimate is 16.27M USD.
The next earnings revenue estimate has been revised downward by 21.9% in the past 3 months. Downward revisions are a negative sign and indicate that analysts are more pessimistic about the next earnings compared to 3 months ago.
Full Analyst Estimates 2026 - 2028
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | ||
|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 79.181M 7.48% | 56.134M -29.11% | 61.858M 10.20% | 86.43M 39.72% | 141.09M 63.24% | 203.62M 44.32% | |
| EBITDA YoY % growth | 4.837M 120.81% | -14.806M -406.10% | -3.914M 73.56% | 12.973M 431.45% | 35.426M 173.07% | N/A | |
| EBIT YoY % growth | 1.07M 103.89% | -18.23M -1,803.74% | -8.172M 55.17% | 10.306M 226.11% | 43.851M 325.49% | N/A | |
| Operating Margin | 1.35% | -32.48% | -13.21% | 11.92% | 31.08% | N/A | |
| EPS YoY % growth | -0.18 89.29% | -1.02 -466.67% | -0.48 53.33% | 0.07 115.54% | 1.04 1,303.45% | 2.11 103.44% |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | Q1 / 27 | Q2 / 27 | Q3 / 27 | Q4 / 27 | |
|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.08 56.08% | 0.01 103.19% | 0.06 162.33% | 0.10 327.28% | 0.02 125.81% | 0.08 1,500.00% | 0.17 209.09% | 0.18 75.61% |
| Revenue Q2Q % growth | 16.267M 23.81% | 19.683M 31.14% | 23.505M 33.32% | 26.975M 67.77% | 25.18M 54.79% | 29.179M 48.24% | 34.613M 47.26% | 35.538M 31.74% |
| EBITDA Q2Q % growth | 643.11K 128.47% | 2.756M 468.94% | 4.494M 170.07% | 5.081M 33.18% | 4.422M 587.60% | 6.776M 145.86% | 10.362M 130.57% | 10.634M 109.29% |
| EBIT Q2Q % growth | -918K 72.38% | 803.423K 127.94% | 2.958M 293.46% | 4.85M 1,194.81% | N/A | N/A | N/A | N/A |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
86.01%
EPS Next 5 Year
N/A
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
45.62%
Revenue Next 5 Year
N/A
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
N/A
EBIT Next 5 Year
N/A
JOURNEY MEDICAL CORP / DERM Forecast FAQ
When does JOURNEY MEDICAL CORP (DERM) report earnings?
JOURNEY MEDICAL CORP (DERM) will report earnings on 2026-05-19.
What are the consensus estimates for JOURNEY MEDICAL CORP (DERM) next earnings?
The consensus EPS estimate for the next earnings of JOURNEY MEDICAL CORP (DERM) is -0.08 USD and the consensus revenue estimate is 16.27M USD.
Can you provide the consensus rating for JOURNEY MEDICAL CORP stock?
The consensus rating for JOURNEY MEDICAL CORP (DERM) is 82 / 100 . This indicates that analysts generally have a positive outlook on the stock.